Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05559580
Registration number
NCT05559580
Ethics application status
Date submitted
26/09/2022
Date registered
29/09/2022
Titles & IDs
Public title
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
Query!
Scientific title
A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel Group, Efficacy and Safety Study of at Least 48 Weeks of Oral BI 685509 Treatment in Adults With Progressive Systemic Sclerosis
Query!
Secondary ID [1]
0
0
2022-500332-11-00
Query!
Secondary ID [2]
0
0
1366-0031
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
VITALISScE™
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Scleroderma, Systemic
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Avenciguat (BI 685509)
Treatment: Drugs - Placebo
Experimental: Avenciguat (BI 685509) - Avenciguat (BI 685509)
Placebo comparator: Placebo - Placebo
Treatment: Drugs: Avenciguat (BI 685509)
Avenciguat (BI 685509)
Treatment: Drugs: Placebo
Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Rate of decline in forced vital capacity (FVC) (mL) over 48 weeks
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
48 weeks.
Query!
Secondary outcome [1]
0
0
Absolute change from baseline in Modified Rodnan Skin Score (mRSS) at Week 48 in study participants with diffuse cutaneous systemic sclerosis (dcSSc)
Query!
Assessment method [1]
0
0
To measure mRSS, skin thickness of the patient is rated by palpation using a scale of 0-3, with 0 = normal skin; 1= mild thickness; 2= moderate thickness and 3=severe thickness with an inability to pinch the skin into a fold (worst outcome).
Query!
Timepoint [1]
0
0
At baseline and at week 48.
Query!
Secondary outcome [2]
0
0
Proportion of responders in study participants with diffuse cutaneous systemic sclerosis (dcSSc) based on the revised Composite Response Index in Systemic Sclerosis (CRISS) at Week 48
Query!
Assessment method [2]
0
0
Revised Composite Response Index in Systemic Sclerosis (CRISS) at Week 48 (Achievement of = 20% improvement from baseline to week 48 in at least 3 of the 5 core set measures, except = 5% in Forced Vital Capacity (FVC) percent predicted). The CRISS is a two-step composite index which includes in Step 2 the mRSS, FVC percent predicted, HAQ-DI, patient's global assessment and clinicians's global assessment. Step 1 in the ACR-CRISS version consists of the absence of significant worsening of interstitial lung disease, a new scleroderma renal crisis, left ventricular failure or pulmonary arterial hypertension. The revised version proposes that the absence of significant gastrointestinal dysmotility requiring parenteral or enteral nutrition and significant digital ischaemia requiring hospitalisation, gangrene or amputation are added to Step 1. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.
Query!
Timepoint [2]
0
0
At baseline and at week 48.
Query!
Secondary outcome [3]
0
0
Absolute change from baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) score at Week 48
Query!
Assessment method [3]
0
0
HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area.
Query!
Timepoint [3]
0
0
At baseline and at week 48.
Query!
Secondary outcome [4]
0
0
American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) score in study participants with diffuse cutaneous systemic sclerosis (dcSSc) at Week 48
Query!
Assessment method [4]
0
0
The CRISS is a two-step composite index which includes in Step 2 the Modified Rodnan Skin Score (mRSS), FVC percent predicted, Health Assessment Questionnaire - Disability Index (HAQ-DI), patient's global assessment and clinicians's global assessment. Step 1 in the ACR-CRISS version consists of the absence of significant worsening of interstitial lung disease, a new scleroderma renal crisis, left ventricular failure or pulmonary arterial hypertension. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.
Query!
Timepoint [4]
0
0
At week 48.
Query!
Secondary outcome [5]
0
0
Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 48
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
At week 48.
Query!
Secondary outcome [6]
0
0
Absolute change from baseline in forced vital capacity (FVC) (% predicted) at Week 48
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
At baseline and at week 48.
Query!
Secondary outcome [7]
0
0
Absolute change from baseline in the Patient Global Assesment (PGA) Visual Analog Scale (VAS) score at Week 48
Query!
Assessment method [7]
0
0
The PGA is a self-assessment on the patient's overall health in the prior 1 week using a 0-10 ordinal scale, with a higher score indicating a worse outcome.
Query!
Timepoint [7]
0
0
At baseline and at week 48.
Query!
Secondary outcome [8]
0
0
Absolute change from baseline in the Clinician Global Assessment (CGA) Visual Analog Scale (VAS) score at Week 48
Query!
Assessment method [8]
0
0
Clinician assessment (CGA) on the patient's overall health in the prior 1 week using a 0-10 ordinal scale, with a higher score indicating a worst outcome.
Query!
Timepoint [8]
0
0
At baseline and at week 48.
Query!
Secondary outcome [9]
0
0
Composite measure of Raynaud's phenomenon (RP) activity at Week 48
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Week 48.
Query!
Secondary outcome [10]
0
0
Absolute change from baseline in Digital ulcer (DU) net burden at Week 48
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
At baseline and at week 48.
Query!
Secondary outcome [11]
0
0
Time to treatment failure
Query!
Assessment method [11]
0
0
Time to treatment failure, defined as the time to one of the following events (whichever occurs first) occurring over the 48-week and extended treatment period:
* death,
* absolute decline in percent-predicted forced vital capacity (FVC) =10% relative to baseline,
* =25% increase in Modified Rodnan Skin Score (mRSS) and an increase in mRSS of \>5 points,
* initiation or dose change of immunomodulating/immunosuppressive therapy for clinically significant deterioration of Diffuse cutaneous systemic sclerosis (dcSSc)
Query!
Timepoint [11]
0
0
48 weeks.
Query!
Secondary outcome [12]
0
0
Time to Modified Rodnan Skin Score (mRSS) progression (=25% increase in mRSS and an increase in mRSS of >5 points) in study participants with diffuse cutaneous systemic sclerosis (dcSSc)
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
48 weeks.
Query!
Secondary outcome [13]
0
0
Proportion of study participants with diffuse cutaneous systemic sclerosis (dcSSc) with Modified Rodnan Skin Score (mRSS) progression (25% increase in mRSS and an increase in mRSS of >5 points)
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
48 weeks.
Query!
Eligibility
Key inclusion criteria
1. Signed and dated written informed consent in accordance with International Council on Harmonisation (ICH) - Good Clinical Practice (GCP) and local legislation prior to admission to the trial.
2. Male or female patients aged =18 years at time of consent (or above legal age, e.g. United Kingdom (UK) =16 years).
3. Patients must fulfill the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for Systemic sclerosis (SSc).
4. Patients must be diagnosed with limited or with diffuse cutaneous SSc as defined by LeRoy et al. (R17 0149). Patients diagnosed with limited cutaneous SSc may be included if they are anti Scl-70 antibody positive.
5. Diffuse cutaneous SSc disease onset (defined by first non-RP symptom) in patients with diffuse cutaneous SSc must be within 7 years of Visit 1. Limited cutaneous SSc onset must be within 2 years of Visit 1.
6. Evidence of active disease, defined as having at least one of the following:
* New onset of SSc within the last 2 years of Visit 1 OR
* New skin involvement or worsening of two new body areas within 6 months of Visit 1 (out of the possible 17 body areas defined by Modified Rodnan Skin Score (mRSS) assessment, documented in clinical files) OR
* New involvement or worsening of one new body area if either chest or abdomen within 6 months of Visit 1 OR
* Worsening of skin thickening (e.g. =2 mRSS points) within 6 months of Visit 1 OR
* =1 tendon friction rub
7. Elevated biomarkers on Visit 1 (screening) defined as at least one of the following:
* C-reactive protein (CRP) =6 mg/L (=0.6 mg/dL), OR
* Erythrocyte sedimentation rate (ESR) =28 mm/h, OR
* Krebs von den Lungen 6 (KL-6) =1000 U/mL If none of the three criteria are met or respective test results should not be available, the patient can be entered if the modified Disease Activity Index (mDAI) is = 2.5.
8. Evidence of significant vasculopathy, defined as:
* Active Digital ulcer (DU(s)) on Visit 1 OR
* Documented history of DU(s), OR
* Previous treatment of RP with prostacyclin analogues or = 1 other medications, including calcium channel blockers, nitrates,, NO donors in any form, including topical; phosphodiesterase 5 (PDE5) inhibitors (e.g. sildenafil, tadalafil, vardenafil); nonspecific PDE5 inhibitors (theophylline, dipyridamole) OR
* RP with elevated CRP =6 mg/L
* If none of the four criteria above are met, the patient can be entered if the diagnosis of Interstitial lung disease (ILD) has been confirmed Further inclusion criteria apply.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Any known form of pulmonary hypertension.
2. Pulmonary disease with FVC <50% of predicted. at screening.
3. Other autoimmune connective tissue diseases, except for fibromyalgia, scleroderma-associated myopathy and secondary Sjogren syndrome.
4. Diffusing capacity for carbon monoxide (DLCO) (haemoglobin corrected) <40% of predicted at screening.
5. Any history of scleroderma renal crisis within the last 6 months.
6. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (Chronic Kidney Disease Epidemiology (CKD-EPI) formula) or on dialysis at screening.
7. Cirrhosis of any Child-Pugh class (A, B or C).
8. Cholestasis at present, or Alkaline phosphatase (ALP) > 4 x Upper limit of normal (ULN), or ALP > 2 x ULN and Gamma-glutamyl transferase (GGT) > 3 x ULN at Screening.
Further exclusion criteria apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
24/11/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
28/11/2025
Query!
Actual
Query!
Sample size
Target
200
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [2]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [3]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [4]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [5]
0
0
St Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Iowa
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
C.a.b.a
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Caba
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
La Plata
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Mar del Plata
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Graz
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Bruxelles
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Gent
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Leuven
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Liège
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Curitiba
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Porto Alegre
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
São Bernardo do Campo
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
São Paulo
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
British Columbia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Ontario
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Quebec
Query!
Country [33]
0
0
Chile
Query!
State/province [33]
0
0
Comuna De Recoleta
Query!
Country [34]
0
0
Chile
Query!
State/province [34]
0
0
Vitacura
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Beijing
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Bengbu
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Changchun
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Chengdu
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Guangzhou
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Hangzhou
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Nanjing
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Ningbo
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Shanghai
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Suzhou
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Tianjin
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Wenzhou
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Wuhan
Query!
Country [48]
0
0
Czechia
Query!
State/province [48]
0
0
Prague
Query!
Country [49]
0
0
Czechia
Query!
State/province [49]
0
0
Uherske Hradiste
Query!
Country [50]
0
0
Denmark
Query!
State/province [50]
0
0
Aarhus N
Query!
Country [51]
0
0
Finland
Query!
State/province [51]
0
0
Kuopio
Query!
Country [52]
0
0
Finland
Query!
State/province [52]
0
0
Turku
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Epagny Metz-Tessy
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Nantes
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Paris
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Rennes
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Strasbourg
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Toulouse
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Berlin
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Düsseldorf
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Erlangen
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Frankfurt
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Heidelberg
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Jena
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Köln
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
München
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Münster
Query!
Country [68]
0
0
Greece
Query!
State/province [68]
0
0
Athens
Query!
Country [69]
0
0
India
Query!
State/province [69]
0
0
Bangalore
Query!
Country [70]
0
0
India
Query!
State/province [70]
0
0
Chandigarh
Query!
Country [71]
0
0
India
Query!
State/province [71]
0
0
Kochi
Query!
Country [72]
0
0
India
Query!
State/province [72]
0
0
Kolkata
Query!
Country [73]
0
0
India
Query!
State/province [73]
0
0
Maharashtra
Query!
Country [74]
0
0
India
Query!
State/province [74]
0
0
New Delhi
Query!
Country [75]
0
0
India
Query!
State/province [75]
0
0
Pune
Query!
Country [76]
0
0
India
Query!
State/province [76]
0
0
Secunderabad
Query!
Country [77]
0
0
Israel
Query!
State/province [77]
0
0
Haifa
Query!
Country [78]
0
0
Israel
Query!
State/province [78]
0
0
Kfar-Saba
Query!
Country [79]
0
0
Israel
Query!
State/province [79]
0
0
Nahariya
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Ramat Gan
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Ancona
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Brescia
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Firenze
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Genova
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Milano
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Modena
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Roma
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Aichi, Nagoya
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Aichi, Toyoake
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Fukui, Yoshida-gun
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Fukuoka, Kitakyushu
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Gunma, Maebashi
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Hokkaido, Sapporo
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Ishikawa, Kanazawa
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Kyoto, Kyoto
Query!
Country [96]
0
0
Japan
Query!
State/province [96]
0
0
Miyagi, Sendai
Query!
Country [97]
0
0
Japan
Query!
State/province [97]
0
0
Nagasaki, Nagasaki
Query!
Country [98]
0
0
Japan
Query!
State/province [98]
0
0
Osaka, Suita
Query!
Country [99]
0
0
Japan
Query!
State/province [99]
0
0
Osaka, Takatsuki
Query!
Country [100]
0
0
Japan
Query!
State/province [100]
0
0
Tokyo, Bunkyo-ku
Query!
Country [101]
0
0
Japan
Query!
State/province [101]
0
0
Wakayama, Wakayama
Query!
Country [102]
0
0
Korea, Republic of
Query!
State/province [102]
0
0
Seoul
Query!
Country [103]
0
0
Malaysia
Query!
State/province [103]
0
0
Kuala Lumpur
Query!
Country [104]
0
0
Malaysia
Query!
State/province [104]
0
0
Selangor
Query!
Country [105]
0
0
Mexico
Query!
State/province [105]
0
0
Chihuahua
Query!
Country [106]
0
0
Mexico
Query!
State/province [106]
0
0
Guadalajara
Query!
Country [107]
0
0
Mexico
Query!
State/province [107]
0
0
Merida
Query!
Country [108]
0
0
Mexico
Query!
State/province [108]
0
0
Oaxaca
Query!
Country [109]
0
0
Netherlands
Query!
State/province [109]
0
0
Leiden
Query!
Country [110]
0
0
Netherlands
Query!
State/province [110]
0
0
Nijmegen
Query!
Country [111]
0
0
New Zealand
Query!
State/province [111]
0
0
Hamilton
Query!
Country [112]
0
0
Philippines
Query!
State/province [112]
0
0
Manila
Query!
Country [113]
0
0
Philippines
Query!
State/province [113]
0
0
Quezon City
Query!
Country [114]
0
0
Poland
Query!
State/province [114]
0
0
Krakow
Query!
Country [115]
0
0
Poland
Query!
State/province [115]
0
0
Poznan
Query!
Country [116]
0
0
Poland
Query!
State/province [116]
0
0
Warsaw
Query!
Country [117]
0
0
Romania
Query!
State/province [117]
0
0
Bacau
Query!
Country [118]
0
0
Romania
Query!
State/province [118]
0
0
Brasov
Query!
Country [119]
0
0
Romania
Query!
State/province [119]
0
0
Bucharest
Query!
Country [120]
0
0
Romania
Query!
State/province [120]
0
0
Bucuresti
Query!
Country [121]
0
0
Romania
Query!
State/province [121]
0
0
Cluj-Napoca
Query!
Country [122]
0
0
Romania
Query!
State/province [122]
0
0
Constanta
Query!
Country [123]
0
0
Romania
Query!
State/province [123]
0
0
Ramnicu-Valcea
Query!
Country [124]
0
0
Singapore
Query!
State/province [124]
0
0
Singapore
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Barcelona
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Madrid
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Santiago de Compostela
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Valencia
Query!
Country [129]
0
0
Sweden
Query!
State/province [129]
0
0
Göteborg
Query!
Country [130]
0
0
Switzerland
Query!
State/province [130]
0
0
St. Gallen
Query!
Country [131]
0
0
Switzerland
Query!
State/province [131]
0
0
Zürich
Query!
Country [132]
0
0
Taiwan
Query!
State/province [132]
0
0
Taichung
Query!
Country [133]
0
0
Taiwan
Query!
State/province [133]
0
0
Taipei
Query!
Country [134]
0
0
Thailand
Query!
State/province [134]
0
0
Chiang Mai
Query!
Country [135]
0
0
Thailand
Query!
State/province [135]
0
0
Hat Yai
Query!
Country [136]
0
0
Thailand
Query!
State/province [136]
0
0
Muang
Query!
Country [137]
0
0
Thailand
Query!
State/province [137]
0
0
Ratchathewi
Query!
Country [138]
0
0
Turkey
Query!
State/province [138]
0
0
Antalya
Query!
Country [139]
0
0
Turkey
Query!
State/province [139]
0
0
Elazig
Query!
Country [140]
0
0
United Kingdom
Query!
State/province [140]
0
0
Leeds
Query!
Country [141]
0
0
United Kingdom
Query!
State/province [141]
0
0
Liverpool
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
London
Query!
Country [143]
0
0
United Kingdom
Query!
State/province [143]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype called diffuse cutaneous systemic sclerosis. People with another subtype called limited cutaneous systemic sclerosis can also participate if they are anti Scl-70 antibody positive. Systemic sclerosis is also called scleroderma. The purpose of this study is to find out whether a medicine called Avenciguat (BI 685509) helps people with scleroderma who have symptoms due to lung fibrosis or vascular problems. Participants are put into 2 groups by chance. One group takes Avenciguat (BI 685509) tablets 3 times a day and the other group takes placebo tablets 3 times a day. Placebo tablets look like BI 685509 tablets but do not contain any medicine. Participants take the tablets for at least 11 months. Afterwards, participants can continue to take the tablets until the last participant has completed the 11-months treatment period. This means that the time in the study and duration of treatment is different for each participant, depending on when they start the study. At the beginning of the study, participants visit the study site every 2 weeks. The time between the visits to the study site gets longer over the course of the study. After the 11-months treatment period, participants visit the study site every 3 months. During the study, participants regularly do lung function tests. The results are compared between the 2 groups to see whether the treatment works. The participants also regularly fill in questionnaires about their scleroderma symptoms. The doctors regularly check participants' skin condition and general health and take note of any unwanted effects.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05559580
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-800-243-0127
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Query!
Available to whom?
For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.mystudywindow.com/msw/datasharing
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05559580